Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients

Authors:

Abstract
In-centre haemodialysis (HD) patients have a greater risk of sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and more significant mortality associated with coronavirus disease 2019 (COVID-19) than the general population [ 1, 2], which made their vaccination a priority for healthcare authorities [ 3]. Even though real-world data on vaccine efficacy in preventing severe COVID-19 in the HD subpopulation are lacking, and antibody levels have only been indirectly associated with viral neutralization [ 4], several published studies have evaluated the humoral response of these patients after completing vaccination with mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines in terms of seroconversion and intensity (i.e. antibody levels) as an efficacy surrogate, with satisfactory results. The results were similar to those observed in the general population except for patients receiving immunosuppressive medication during vaccination [ 5–7]. Recently there has been evidence of persistent, although declining [ 8], antibody positivity in healthy vaccinated individuals with both mRNA-1273 and BNT162b2 vaccines 3 and 6 months after completing vaccination [ 9–12]. Given the known impaired cellular and humoral responses of HD patients to other immunization programs (e.g. hepatitis B, influenza) [ 13, 14], there was concern regarding the durability of the SARS-CoV-2 vaccine’s effect in this population. Therefore we aimed to determine anti-spike S1 receptor-binding domain (anti-S1-RBD) immunoglobulin G (IgG) presence and degree of decline 3 months after completing vaccination.

This publication has 14 references indexed in Scilit: